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Simple Summary: The impact of cancer on the acute prognosis of stroke patients remains largely
unknown. Furthermore, the usage of interventions aiming to restore cerebral blood flow in ischaemic
stroke, such as thrombolysis and thrombectomy, remains uncharacterised in cancer patients. We
aimed to delineate these relationships using a sample representative of 1,106,045 acute ischaemic
stroke admissions across the US between 2015–2017, 3.51% of whom had cancer. We found that
non-metastatic and metastatic cancers were associated with significantly increased odds of in-hospital
mortality, prolonged hospitalisation and decreased odds of home discharge. We also determined
that both thrombolysis and thrombectomy offset the association between non-metastatic cancer and
in-hospital mortality. Thrombectomy offset the association between metastatic cancer and in-hospital
mortality. We conclude that cancer patients warrant robust stroke prevention, given their increased
odds of adverse outcomes. Thrombolysis and thrombectomy should be considered routinely in
stroke patients with cancer unless otherwise contraindicated.
Abstract: Whilst cancer is a risk factor for acute ischaemic stroke (AIS), its impact on AIS prognosis
between metastatic and non-metastatic (MC and NMC) disease is poorly understood. Furthermore,
the receipt of intravenous thrombolysis (IVT) and endovascular thrombectomy (ET) and their out-
comes is poorly researched. AIS admissions from the National Inpatient Sample (NIS) were included
(October 2015–December 2017). Multivariable logistic regressions adjusting for a wide range of con-
founders analysed the relationship between NMC and MC and AIS in-hospital outcomes (mortality,
prolonged hospitalisation >4 days and routine home discharge). Interaction terms with IVT and
ET were also computed to explore their impact amongst cancer patients. A total of 221,249 records
representative of 1,106,045 admissions were included. There were 38,855 (3.51%) AIS admissions
with co-morbid cancer: NMC = 53.78% and MC = 46.22%. NMC was associated with 23% increased
odds of in-hospital mortality (odds ratio (95% confidence interval) = 1.23 (1.07–1.42)), which was
mainly driven by pancreatic and respiratory cancers. This association was entirely offset by both IVT
and ET. MC was associated with two-fold increased odds of in-hospital mortality (2.16 (1.90–2.45)),
which was mainly driven by respiratory, pancreatic and colorectal cancers. This association was only
offset by ET. Both NMC and MC were significantly associated with prolonged hospitalisation and
decreased odds of routine discharge. Cancer patients are at higher odds of acute adverse outcomes
after AIS and warrant robust primary prevention. IVT and ET improve these outcomes and should
thus be offered routinely unless otherwise contraindicated in this group of stroke patients.
Keywords: ischaemic stroke; cancer; mortality; revascularisation; thrombolysis; thrombectomy
1. Introduction
Malignancy is associated with increased risk of acute ischaemic stroke (AIS) [1]. This
is mediated through a variety of mechanisms, including hypercoagulability [2] and shared
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risk factors [1]. Cancer is therefore important to consider in AIS, as it may not only
be more prevalent amongst AIS patients [3], but may also be associated with adverse
outcomes [4,5]. Despite that fact that cancer is a heterogenous disease, the distribution
of organ-specific primary cancer types amongst a representative sample of AIS patients
remains undescribed. Furthermore, the individual associations between each cancer type
and adverse AIS outcomes remain largely unknown.
Revascularisation therapies (intravenous thrombolysis (IVT) and endovascular throm-
bectomy (ET)) significantly improve AIS outcomes [6,7] and are thus recommended rou-
tinely in eligible patients [8]. Nevertheless, co-morbid cancer may hinder their use given
that this population is more likely to exhibit contraindications to IVT or ET [1]. Current
guidelines recommend IVT in AIS patients with systemic malignancy provided they have a
life expectancy >6 months and no contraindications [8]. These recommendations are based
on limited evidence, as landmark randomised controlled trials studying IVT [9–12] or ET [7]
have excluded cancer patients. Previous smaller scale observational studies of AIS patients
with cancer have found no increased haemorrhagic complications or mortality associated
with IVT [13–15]. Nevertheless, guidelines currently provide no specific recommendations
regarding ET for this population [8], with the efficacy and safety of ET amongst AIS patients
with cancer being largely unclear. While several small retrospective studies have found no
association between cancer and adverse outcomes in AIS patients undergoing ET [16,17],
others have identified significantly higher mortality in cancer patients [18].
This drives the need for a comprehensive description of the association between
cancer and AIS outcomes in contemporary clinical practice and whether revascularisation
therapies have an effect on these outcomes. In this study, using a representative sample
of AIS admissions in the United States (US) between 2015–2017, we sought examine the
prevalence of comorbid cancer among patients with AIS and its association with in-hospital
outcomes, also stratifying by metastatic disease. We also aimed to examine the effect of
IVT/ET on outcomes in cancer patients through the use of interaction terms.
2. Materials and Methods
This study was conducted in accordance with the principles of the Declaration of
Helsinki (1975) and later amendments. The data that support the findings of this study are
available from the corresponding author upon reasonable request.
2.1. Data Source and Inclusion Criteria
The National Inpatient Sample (NIS) is a publicly available database containing
>7 million annual hospital admission records. NIS contains admission records representing
a 20% stratified sample of all community hospital admissions in the United States. Using
the provided sampling weights, the NIS data can be used to provide national estimates
for the sampling population, representative of ~95% of the US population [19,20]. Prior to
undertaking this project, all authors completed the Healthcare Cost and Utilisation Project
(HCUP) Data Use Agreement Training Tool. All authors also read and signed the Data
Use Agreement for Nationwide Databases. As the NIS is publicly available and contains
no patient identifiable information, no ethical approval was needed. Using data files
containing annual admissions between 2015–2017, all records with a primary diagnosis
of ischaemic stroke (International Classification of Disease—Tenth Edition (ICD-10) codes
I63.0–I63.9) were extracted. Only cases admitted between October 2015–December 2017
were included due to a change in co-morbidity coding (ICD-9 to ICD-10) occurring after
September 2015 [20]. Elective admissions and those with missing data on key variables
were excluded.
2.2. Statistical Analysis
All analyses were performed using Stata 15.1SE, Stata Statistical Software. A 5%
threshold of statistical significance was utilised for all analyses (p < 0.05). Analyses were
performed following HCUP guidelines [21], utilising the provided discharge weights as
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probability weights and survey data analysis techniques stratifying by NIS stratum and
year of admission [22] in order to account for patient clustering within hospitals and
produce US-wide estimates [23].
2.2.1. Outcomes
The following outcomes were analysed: (1) in-hospital mortality, (2) prolonged hos-
pital stay in excess of 4 days and (3) routine discharge from hospital. Vital status upon
hospital discharge (dead/alive) and the length of stay (LoS) in hospital are provided as stan-
dard variables in the NIS [24,25]. Prolonged hospitalisation was defined as LoS > 4 days,
according to expert clinical opinion and previous studies assessing ischaemic stroke out-
comes amongst patients admitted to hospital in the United States [26]. A dichotomous
variable indicating patients hospitalised for >4 days was subsequently used as an outcome
for LoS analyses. Discharge status was coded using the provided discharge destina-
tion [27]. All records of patients who were discharged against medical advice and those
discharged to an unknown destination were excluded from the analyses prior to weight-
ing (n = 2187 (0.99%)), allowing estimates for this particular outcome to be provided for
1,095,110 (99.01%) of AIS patients. Discharge destination was then dichotomised into “rou-
tine discharges” and other discharges (“home health care”, “short-term hospital”, “other
facilities including intermediate care and skilled nursing home” and “died in hospital”).
The “other discharges” category was subsequently used as a reference category in all
analyses evaluating discharge destination.
2.2.2. Exposures and Confounders
Co-morbid solid organ cancers (non-metastatic and metastatic) as well as the organ-
specific types were the exposures of interest. Haematological cancers were not considered
part of the exposure, as they form a distinct clinical entity with a different natural course.
Nevertheless, all analyses were adjusted for co-morbid haematological malignancies. Co-
morbid cancer diagnoses were identified using the Clinical Classification Software Refined
(CCSR) codes (Table S1) [28] and represent diagnoses assigned before or during the index
acute ischaemic stroke hospitalisation. Patients with a previous history of cancer (ICD-
10 Z85.x and Z86.0x) but without an ICD-10 code indicating an active cancer diagnosis
(ICD-10 C00-C79) were included in the no active cancer group, the reference category. The
Elixhauser co-morbidities solid tumour without metastases and metastatic cancer were
used to ascertain the presence of metastatic disease [29]. Specific cancer types were also
identified using the individual Clinical Classification Software Refined (CCSR) codes listed
in Table S1.
All models were adjusted for the following confounders: age, sex, ethnicity, Elixhauser
co-morbidities (congestive heart failure, valvular disease, pulmonary circulatory disease,
peripheral vascular disease, paralysis, other neurological disorders, chronic pulmonary
disease, diabetes, hypothyroidism, renal failure, liver disease, peptic ulcer disease, acquired
immune deficiency syndrome, rheumatoid arthritis, coagulopathy, obesity, weight loss,
fluid and electrolyte disorders, anaemia, alcohol abuse, drug abuse, psychosis, depression
and hypertension), previous history of cancer, haematological malignancies, other co-
morbidities (dyslipidaemia, smoking, Parkinson disease, coronary heart disease, all-cause
bleeding, pulmonary embolism, deep venous thrombosis, atrial fibrillation, arrhythmias
other than atrial fibrillation, pneumonia (including aspiration), shock, previous cerebrovas-
cular disease), hospital bedsize, location and teaching status and revascularisation therapy
(thrombolysis, thrombectomy). Adjusting co-variates were selected based on clinical judge-
ment and previous literature [5,14,15,30]. Previous history of cancer was identified using
ICD10 codes Z85.x and Z86.0x. Elixhauser co-morbidities were determined using the
HCUP Elixhauser co-morbidity software version 2020.1 [29]. Co-morbid conditions other
than the Elixhauser co-morbidities were identified using ICD-10 codes (Table S2).
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2.2.3. Descriptive Statistics
Characteristics were compared between AIS hospitalisations without cancer, those
with non-metastatic cancer and those with metastatic disease. One-way analysis of variance
and Pearson’s χ [2] test were employed to compare characteristics for continuous and
categorical variables, respectively. The distribution of each primary cancer type amongst the
included sample as well as the proportion of metastatic disease amongst each cancer type
were determined. Characteristics were then also compared between AIS hospitalisations
with the 5 most common types of primary cancers previously identified. No between-group
tests of statistical significance were performed for these comparisons as the groups were
not mutually exclusive.
2.2.4. Association between Prevalent Cancer and Odds of Receiving
Revascularisation Therapy
Multivariable logistic regressions were employed to analyse the relationship between
co-morbid non-metastatic and metastatic cancer and the odds of receiving IVT and ET in
hospital. All models were adjusted for the covariates listed above, with the exception of
IVT or ET when this variable was used as the outcome.
2.2.5. Association between Non-Metastatic and Metastatic Cancer and
In-Hospital Outcomes
Multivariable logistic regressions were employed to analyse the relationship between
co-morbid non-metastatic and metastatic cancer and in-hospital outcomes. Separate models
containing interaction terms with IVT and ET were also computed to determine whether
these relationships were modified by revascularisation therapies. All models were adjusted
for the covariates listed above.
2.2.6. Association between Non-Metastatic and Metastatic Cancer and In-Hospital
Outcomes amongst Patients Undergoing Endovascular Thrombectomy
Further multivariable logistic regressions were performed in order to explore the
relationship between co-morbid non-metastatic and metastatic cancer and in-hospital
outcomes amongst AIS patients undergoing ET. Separate models including an interaction
term with IVT were also computed in order to determine how outcomes were modified by
whether these patients also received IVT pre-treatment. All models were adjusted for the
covariates listed above.
2.2.7. Association between the Five Most Common Primary Cancer Types and
In-Hospital Outcomes
Multivariable logistic regressions were employed to analyse the relationship between
the five most common primary cancer types and in-hospital outcomes, stratifying each
cancer type by the presence of metastases. All five cancer types were simultaneously
introduced in the same model. All models were adjusted for the covariates listed above as
well as other co-morbid cancer types.
3. Results
Figure 1 details the study population. Out of 230,177 records extracted with a primary
diagnosis of ischaemic stroke between October 2015–December 2017, a total of 8708 elective
admission records as well as 220 records with missing data were excluded, yielding a total
of 221,249 included records. After the application of sampling weights and the exclusion of
strata with single sampling units, the included records were used to provide estimates for
the population from which they were sampled: 1,106,045 hospitalisations with a primary
diagnosis of AIS.
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Figure 1. atient o lation flowchart.
3.1. Descriptive Statistics
Figure 2 details the distribution of primary cancer types amongst the 38,855 AIS hos-
pitalisations with co-morbid cancer, representing 3.51% of the entire included sample. The
five most common types were: respiratory (9490 (24.42%)), prostate (4960 (12.77%)), breast
(3375 (8.69%)), pancreatic (2640 (6.79%)) and colorectal cancers (2490 (6.41%)). There were
4750 (50.05%) hospitalisations with metastatic respiratory cancer, 1250 (25.20%) hospitalisa-
tions with metastatic prostate cancer, 1110 (32.89%) hospitalisations with metastatic breast
cancer, 1875 (71.02%) hospitalisations with metastatic pancreatic cancer and 985 (39.56%)
hospitalisations with metastatic colorectal cancer.
Table 1 and Supplementary Table S3 detail the ch racteristics of the included popu-
lation, representative of 1,106,045 AIS hospitalisations. The median (interquartile range)
age was 72 (61–82) years and 50.41% were female. The median (interquartile range) length
of stay was 3 (2–6) days. There were 20,895 (1.89%) hospitalisations with non-metastatic
cancer and 17,960 (1.62%) with metastatic cancer. Median age ranged between 70 and
75 years, highest among those with non-metastatic cancer and lowest amongst those with
metastatic cancer. The highest proportion of females was recorded amongst admissions
with metastatic cancer (51.03%), followed by those without active cancer (50.47%) and
those with non-metastatic cancer (46.88%). Compared to admissions without cancer, those
with cancer had higher rates of prevalent chronic pulmonary disease, liver disease, coagu-
lopathy and anaemia, but lower rates of congestive heart disease and diabetes. Compared
to admissions without cancer, those with cancer had higher rates of in-hospital mortality,
prolonged hospitalisation and lower rates of routine discharge.
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Figure 2. i tribution of each primary c ncer type amongst the i cluded sample of acute ischaemic
stroke patients, representative of 1,106,045 patients.
Supplementary Table S4 details the characteristics of the included hospitalisations
with the five most common co-morbid cancer types. Those with prostate cancer were oldest,
median (int rquartile range)—79 (71–85) years, followed by those with breast cancer—74
(67–83) years, colorectal cancer—74 (65–82) years, respiratory cancers—71 (63–79) years
and pancreatic cancer 71 (63–77) years. Hospitalisations with pancreatic cancer had the
highest rate of in-hospital mortality (10.61%), followed by respiratory cancers (10.17%),
colorectal cancer (6.22%), breast cancer (5.63%) and prostate cancer (3.73%).
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Table 1. Patient characteristics on admission, stratified by either co-existent non-metastatic or metastatic cancer. Further
descriptive statistics are detailed in Table S3. Statistically significant p values (<0.05) are highlighted in bold.
Variation All No Active Cancer Non-MetastaticCancer Metastatic Cancer p Value
n 1,106,045 1,067,190 20,895 17,960
Age (years),
median (IQR) 72 (61–82) 71 (60–82) 75 (67–83) 70 (62–78) <0.001
Length-of-stay (days),
median (IQR) 3 (2–6) 3 (2–6) 4 (2–7) 4 (2–7) <0.001
Sex
Female, n (%) 557,595 (50.41) 538,635 (50.47) 9795 (46.88) 9165 (51.03) <0.001
Ethnicity <0.001
White 735,330 (66.48) 707,550 (66.30) 15,005 (71.81) 12,775 (71.13)
Black 183,090 (16.55) 177,790 (16.66) 2880 (13.78) 2420 (13.47)
Hispanic 84,950 (7.68) 82,700 (7.75) 1240 (5.93) 1010 (5.62)
Asian or Pacific Islander 31,635 (2.86) 30,500 (2.86) 530 (2.54) 605 (3.37)
Native American 4700 (0.42) 4570 (0.43) 60 (0.29) 70 (0.39)
Other 27,460 (2.48) 26,535 (2.49) 410 (1.96) 515 (2.87)
ELIXHAUSER
CO-MORBIDITIES, n (%)
Congestive Heart Failure 172,170 (15.57) 166,950 (15.64) 3225 (15.43) 1995 (11.11) <0.001
Valvular Disease 110,540 (9.99) 106,640 (9.99) 2300 (11.01) 1600 (8.91) 0.008
Pulmonary Circulation Disease 8460 (0.76) 6710 (0.63) 555 (2.66) 1195 (6.65) <0.001
Peripheral Vascular Disease 112,065 (10.13) 107,955 (10.12) 2470 (11.82) 1640 (9.13) <0.001
Paralysis 112,895 (10.21) 108,920 (10.21) 2260 (10.82) 1715 (9.55) 0.178
Other Neurological Disorders 6620 (0.60) 6275 (0.59) 210 (1.01) 135 (0.75) 0.001
Chronic Pulmonary Disease 174,180 (15.75) 165,690 (15.53) 4795 (22.95) 3695 (20.57) <0.001
Diabetes (without chronic
complications) 210,220 (19.01) 203,765 (19.09) 3520 (16.85) 2935 (16.34) <0.001
Diabetes (with chronic
complications) 214,400 (19.38) 209,135 (19.60) 3095 (14.81) 2170 (12.08) <0.001
Hypothyroidism 159,160 (14.39) 153,810 (14.41) 2950 (14.12) 2400 (13.36) 0.193
Renal Failure 181,950 (16.45) 175,960 (16.49) 3670 (17.56) 2320 (12.92) <0.001
Liver Disease 18,310 (1.66) 17,275 (1.62) 550 (2.63) 485 (2.70) <0.001
Peptic Ulcer Disease 7695 (0.70) 7400 (0.69) 175 (0.84) 120 (0.67) 0.527
Acquired Immune Deficiency
Syndrome 2395 (0.22) 2280 (0.21) 100 (0.48) 15 (0.08) <0.001




30,150 (2.73) 29,240 (2.74) 520 (2.49) 390 (2.17) 0.075
Coagulopathy 41,405 (3.74) 37,105 (3.48) 1560 (7.47) 2740 (15.26) <0.001
Obesity 145,465 (13.15) 142,575 (13.36) 1775 (8.49) 1115 (6.21) <0.001
Weight loss 44,030 (3.98) 39,685 (3.72) 1795 (8.59) 2550 (14.20) <0.001
Fluid and electrolyte disorders 246,680 (22.30) 235,750 (22.09) 5200 (24.89) 5730 (31.90) <0.001
Anaemia (chronic blood loss) 4025 (0.36) 3590 (0.34) 240 (1.15) 195 (1.09) <0.001
Anaemia (deficiency) 133,005 (12.03) 123,720 (11.59) 4375 (20.94) 4910 (27.34) <0.001
Alcohol abuse 49,375 (4.46) 48,080 (4.51) 800 (3.83) 495 (2.76) <0.001
Drug abuse 28,985 (2.62) 28,365 (2.66) 355 (1.70) 265 (1.48) <0.001
Psychoses 26,255 (2.37) 25,490 (2.39) 440 (2.11) 325 (1.81) 0.041
Depression 124,635 (11.27) 120,280 (11.27) 2330 (11.15) 2025 (11.28) 0.971
Hypertension 946,140 (85.54) 916,430 (85.87) 16,975 (81.24) 12,735 (70.91) <0.001
PROCEDURES, n (%)
Thrombectomy 34,420 (3.11) 33,090 (3.10) 670 (3.21) 660 (3.67) 0.139
Thrombolysis 103,600 (9.37) 101,035 (9.47) 1730 (8.28) 835 (4.65) <0.001
OUTCOMES, n (%)
In-hospital mortality 43,545 (3.94) 40,545 (3.80) 1230 (5.89) 1770 (9.86) <0.001
Length-of-stay >4 days 380,605 (34.41) 363,430 (34.05) 8680 (41.54) 8495 (47.30) <0.001
Routine Discharge 394,105 (35.99) 384,490 (36.39) 5600 (26.94) 4015 (22.52) <0.001
3.2. Association between Prevalent Cancer and Odds of Receiving Revascularisation Therapy
Supplementary Table S5 details the results of the multivariable logistic regressions
evaluating the associations between non-metastatic and metastatic cancer and the odds of
receiving thrombolysis or thrombectomy. Compared to hospitalisations without cancer,
those with non-metastatic cancer had lower odds of receiving both IVT (odds ratio (95%
confidence interval)—0.77 (0.66–0.90)) and ET (0.80 (0.63–0.9994)). Compared to hospitali-
sations without cancer, those with metastatic cancer had lower odds of receiving IVT (0.39
(0.32–0.47)), but not ET (0.87 (0.69–1.09)).
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3.3. Association between Non-Metastatic and Metastatic Cancer and In-Hospital Outcomes
Figure 3 details the results of the multivariable logistic regressions assessing the
associations between non-metastatic and metastatic cancer and in-hospital outcomes. Non-
metastatic cancer was associated with a 23% increase in the odds of in-hospital mortality
(odds ratio (95% confidence interval)—1.23 (1.07–1.42)). This association exhibited signifi-
cant interactions with IVT and ET: non-metastatic cancer was not associated with increased
in-hospital mortality amongst AIS hospitalisations undergoing either IVT or ET. Metastatic
cancer was associated with a 2-fold increase in the odds of in-hospital mortality: 2.16
(1.90–2.45). This association also exhibited a significant interaction with ET, but not IVT:
metastatic cancer was not associated with increased in-hospital mortality amongst AIS
patients undergoing ET. Non-metastatic and metastatic cancers were also associated with
increased odds of prolonged hospitalisation and decreased odds of routine discharge.




Figure 3. Results of multivariable logistic regressions assessing the association between co-morbid cancer (non-metastatic 
and metastatic) and acute ischaemic stroke in-hospital outcomes as well as the interaction with revascularisation therapies. 
OR—odds ratio; CI—confidence interval; IVT—intravenous thrombolysis; ET—endovascular thrombectomy; P (int)—p 
value for interaction term. 
Figure 3. Results of multivariable logistic regressions assessing the association between co-morbid
cancer (non-metastatic and metastatic) and acute ischaemic stroke in-hospital outc es as well as the
interaction with revascularisation therapies. OR—odds ratio; CI—confidence interval; IVT—intravenous
thrombolysis; ET—endovascular thrombectomy; P (int)—p value for interaction term.
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3.4. Association between Non-Metastatic and Metastatic Cancer and In-Hospital Outcomes
amongst Patients Undergoing Endovascular Thrombectomy
Figure 4 details the results of the multivariable logistic regression assessing the rela-
tionship between non-metastatic and metastatic cancer and in-hospital outcomes amongst
AIS patients undergoing ET. In this group, neither non-metastatic nor metastatic cancer
was associated with significantly increased odds of in-hospital mortality or prolonged
hospitalisation. These relationships did not significantly differ amongst patients receiving
pre-treatment with IVT. Similarly, neither non-metastatic nor metastatic cancer was associ-
ated with decreased odds of routine home discharge amongst AIS patients undergoing ET.
While the relationship between non-metastatic disease and routine home discharge did not
differ based on IVT pre-treatment, patients with metastatic disease undergoing IVT before
ET were significantly more likely to be discharged home than those only undergoing ET
(p = 0.031).




Figure 4. Results of multivariable logistic regressions assessing the association between co-morbid cancer (non-metastatic 
and metastatic) and acute ischaemic stroke in-hospital outcomes amongst AIS patients undergoing endovascular throm-
bectomy. Separate models containing interaction terms with intravenous thrombolysis therapy were constructed to deter-
mine whether outcomes were modified by IVT pre-treatment. OR—odds ratio; CI—confidence interval; IVT—intravenous 
thrombolysis; ET—endovascular thrombectomy; P (int)—p value for interaction term. 
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Figure 5 details the results of the multivariable logistic regression assessing the asso-
ciation between the five most common primary cancer types and in-hospital outcomes, 
stratifying by metastatic disease status. Respiratory cancers (both non-metastatic—1.88 
(1.48–2.40) and metastatic—2.40 (1.90–3.02)), pancreatic cancers (both non-metastatic (1.96 
(1.04–3.71)) and metastatic—2.33 (1.61–3.37)) and metastatic colorectal cancer (2.08 (1.21–
3.58)) were associated with significantly increased in-hospital mortality. There were no 
associations between metastatic prostate cancer, breast cancer (both non-metastatic and 
metastatic) and non-metastatic colorectal cancer and in-hospital mortality. Non-metastatic 
prostate cancer was associated with decreased odds of in-hospital mortality (0.62 (0.40–
0.96)). Respiratory cancers, metastatic pancreatic and metastatic colorectal cancer were as-
sociated with increased odds of prolonged hospitalisation. Respiratory cancers, metastatic 
prostate cancer, pancreatic cancer (both non-metastatic and metastatic) and metastatic col-
orectal cancer were associated with decreased odds of routine discharge. 
Figure 4. Results of multivariable logistic regressions assessing the association between co-morbid
cancer (non-metastatic a d metastatic) and acute ischaemic stroke in- os ital outcomes amongst AIS
patients undergoing endovascular thrombectomy. Separate models containing interaction terms with
intravenous thrombolysis therapy were constructed to determine whether outcomes were modified
by IVT pre-treatment. OR—odds ratio; CI—confidence interval; IVT—intravenous thrombolysis;
ET—endovascular thrombectomy; P (int)—p value for interaction term.
3.5. Association between the Five Most Common Primary Cancer Types and In-Hospital Outcomes
Figure 5 details the results of the multivariable logistic regression assessing the associa-
tion between the five most common primary cancer types and in-hospital outcomes, stratify-
ing by metastatic disease status. Respiratory cancers (both non-metastatic—1.88 (1.48–2.40)
and metastatic—2.40 (1.90–3.02)), pancreati cancers (both no -met static (1.96 (1.04–3.71))
and metastatic—2.33 (1.61–3.37)) and metastatic colorectal cancer (2.08 (1.21–3.58)) were
associated with significantly increased in-hospital mortality. There were no associations
between metastatic pro te cancer, breast cancer (both non-metastatic nd metastatic) and
non-metastatic colorectal cancer and in-hospital mortality. Non-metastatic prostate cancer
was associated with decreased odds of in-hospital mortality (0.62 (0.40–0.96)). Respiratory
cancers, metastatic pancreatic and metastatic colorectal cancer were associated with in-
creased odds of prolonged hospitalisation. Respiratory cancers, metastatic prostate cancer,
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pancreatic cancer (both non-metastatic and metastatic) and metastatic colorectal cancer
were associated with decreased odds of routine discharge.




Figure 5. Results of multivariable logistic regressions assessing the association between the 5 most 
commonly occurring cancer types in the included cohort and acute ischaemic stroke in-hospital 
mortality as well as the interaction with revascularisation therapies. OR—odds ratio; CI—confi-
dence interval; IVT—intravenous thrombolysis; ET—endovascular thrombectomy. 
Fi . esults of multivariab e logistic gres ions assessing the ssociation be ween the 5 most
commonly occurring cancer types in the included cohort and acute ischaemic stroke in-hospital
mortality as well as the interaction with revascularisation therapies. OR—odds ratio; CI—confidence
interval; IVT—intravenous thrombolysis; ET—endovascular thrombectomy.
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4. Discussion
In this study, including a sample representative of 1,106,045 acute ischemic stroke
admissions between 2015–2017, we have determined the distribution of prevalent cancers
as well as their association with in-hospital outcomes. We have also determined how these
associations are influenced by the use of revascularisation therapies.
The five most common cancer types were: respiratory (24.42%), prostate (12.77%),
breast (8.69%), pancreatic (6.79%) and colorectal cancers (6.41%). We report significant
differences in stroke treatment according to cancer diagnosis, with patients with non-
metastatic cancer at 23% lower odds of receiving IVT and 20% lower odds of receiving
ET. The disparities in treatments were even greater in patients with metastatic cancer who
were at 61% lower odds of receiving IVT compared to patients without cancer. Patients
with cancer were at increased risk of adverse AIS outcomes. Non-metastatic cancer was
associated with 23% increased odds of in-hospital mortality, which was mainly driven
by pancreatic (96% increased odds) and respiratory (88% increased odds) cancers. This
association was entirely offset by both IVT and ET. Metastatic cancer was associated with
2-fold increased odds of in-hospital mortality, which was mainly driven by respiratory
(2.43-fold increase), pancreatic (2.37-fold increase) and colorectal (2.11-fold) cancers. This
association was only offset by ET. Non-metastatic cancer was also associated 16% decreased
odds of routine discharge, which was mainly driven by pancreatic (48% decreased odds)
and respiratory (35%) cancers. This association was offset by IVT but not by ET. Metastatic
cancer was associated with 40% decreased odds of routine discharge, mainly driven
by pancreatic (54% decreased odds), respiratory (47%), colorectal (32%), prostate (28%)
and breast cancers (27%). This association was offset by ET and ET + IVT, but not by
IVT alone. Similarly, non-metastatic and metastatic cancers were also associated with
prolonged hospitalisation.
The association between co-morbid cancer and AIS outcomes has been previously
evaluated on smaller, single-centre cohorts [4,31,32]. A previous investigation including
~5000 AIS patients out of whom 1.46% had co-morbid cancer found a 3.7-fold increase in the
odds of in-hospital mortality [4]. Another study including 468 AIS patients with co-morbid
cancer found that metastatic disease was independently associated with a 4.5-fold increase
in the risk of 6-month mortality compared to non-metastatic cancers [32]. Furthermore,
gastric and pancreatic cancers were associated with increased mortality risk compared to
other cancer types [32]. Our results complement these previous findings by providing a
comprehensive description of the association between these disease entities based on a
large, national real-world sample of AIS patients and highlight disparities in provision of
evidence-based therapies.
Furthermore, our results provide additional insight into these relationships by explor-
ing differences based on the presence of metastases and between different primary types.
We found 23% increased odds of in-hospital mortality and 16% decreased odds of routine
home discharge associated with non-metastatic cancer, which may be attributed to a higher
proportion of cryptogenic strokes [4] with worse prognosis [33] and increased hypercoagu-
lability leading to complications such as venous thromboembolism, recurrent stroke [34]
and a greater risk of haemorrhagic transformation. Another important contributor to the
increased risk of adverse outcomes was significant differences in the receipt of IVT and ET,
with patients with cancer consistently less likely to receive revascularisation therapies. This
may be related to differences in the time to hospital presentation between patients with and
without cancer, as well as likely increased prevalence of contraindications to IVT, such as
thrombocytopaenia, previous anticoagulation and recent surgery, amongst cancer patients.
Previous large clinical trials assessing the use of IVT for AIS revascularisation provide
no specific information regarding AIS patients with cancer [9–12]. Nevertheless, several ob-
servational studies including AIS patients with co-morbid cancer have found no association
between IVT and in-hospital mortality, major bleeding or functional outcomes [13,14,35–38],
while current guidelines recommend IVT in patients with systemic malignancy provided
they have a life expectancy >6 months and no other contraindications [8]. We found that
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even after comprehensive adjustment, patients with co-morbid cancer were less likely to
receive IVT, suggesting that the lower rates of IVT in this population may not be fully
explained by a higher prevalence of contraindications. This may reflect the fact that treating
clinicians may be hesitant to use IVT solely based on cancer status, even in those with
non-metastatic disease.
Our work shows for the first time that IVT offset the increased in-hospital mortality
and decreased odds of routine discharge associated with non-metastatic cancer, providing
supportive evidence for IVT therapy in these patients. Nevertheless, the associations
between metastatic cancer and adverse in-hospital outcomes were not offset by IVT, sug-
gesting that AIS patients with metastatic cancer may not fully benefit from this therapy.
This may relate to the fact that strokes in this patient group may be misdiagnosed cerebral
metastases presenting as a stroke mimic. Furthermore, a greater likelihood of haemorrhagic
transformation in this patient group may offset any benefit with thrombolysis. However,
we also found that IVT pre-treatment was associated with a significant increase in the odds
of routine home discharge in patients with metastatic cancer undergoing ET, suggesting
a potentially different treatment effect in this patient group. Nevertheless, these results
need to be interpreted in the light of the limitations inherent to the small sample size of the
included patient group with cancer undergoing ET.
As with IVT, clinical trials assessing the use of ET in AIS provide no specific data
regarding its use in cancer patients [7]. Nevertheless, a few small retrospective observa-
tional studies have assessed the use of ET in Asian AIS patients with cancer, reaching
different conclusions [16,17,32]. While similar acute outcomes were found amongst AIS
patients with and without co-morbid cancer undergoing ET in two studies [16,17], a third
study found significantly worse functional outcomes in cancer patients treated with ET [18].
Furthermore, it has been postulated that AIS patients with cancer may have different clot
composition, which may hinder successful recanalisation in this population [16].
Our analysis shows that patients with non-metastatic cancer were significantly less
likely to receive ET, while those with metastatic disease were equally likely to receive ET
compared to patients without cancer. These differences may reflect the fact that metastatic
cancer patients may be more likely to present with cardioembolic strokes caused large
artery occlusion, rendering them more likely candidates for ET. Nevertheless, in the ab-
sence of more granular stroke syndrome data, we could not assess this hypothesis and
further research is thus warranted. Our study provides for the first time an analysis of
the relationship between cancer and ET in AIS patients using a large, real-world and
contemporary sample. ET offset the excess odds of in-hospital adverse outcomes associated
both with non-metastatic and metastatic cancers, suggesting that ET may be a successful
strategy in eligible patients with cancer, especially in those with metastases who may
not fully benefit from IVT. Our findings also suggest that concomitant IVT and ET treat-
ment further improves the odds of routine home discharge in patients with metastatic
cancer and may be considered in such patients without specific contraindications to either
revascularisation strategy.
Our study has several strengths, such as including a large sample representative
of >1 million AIS admissions between late 2015–2017 across the United States as well
as having adjusted for a wide range of important confounders. Our results thus reflect
contemporary stroke management, including the more widespread adoption of ET and
thus allow the generalisation of clinical implications to patients with similar characteristics.
Our findings show that both non-metastatic and metastatic disease are associated with
significant increases in in-hospital mortality, prolonged hospitalisation and decreased odds
of routine home discharge. This highlights that cancer patients warrant thorough primary
prevention, since they are not only more likely to suffer an incident stroke, but also at
higher odds of acute adverse stroke outcomes. Given our large sample size, our study is
able to provide more granular information regarding individual associations between each
primary cancer type and adverse acute outcomes.
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Our study highlights inequalities in the receipt of evidence-based reperfusion thera-
pies in cancer patients. Such differences have also been described in other cardiovascular
conditions such as myocardial infarction [28]. We report that cancer patients offered treat-
ment with IVT or ET may derive a benefit and that IVT may offset the non-metastatic
cancer-associated excess odds of adverse outcomes. Furthermore, ET offsets the excess
odds associated with both non-metastatic and metastatic disease. Along with previous find-
ings, our study also suggests that co-morbid cancer should not represent a contraindication
to AIS revascularisation therapies in itself.
Naturally, our study also has limitations. Having used administrative data, we
defined AIS using ICD-10 codes and thus lacked more detailed information regarding
stroke severity or classification. Nevertheless, all analyses were adjusted for a wide range
of confounders including some important predictors of severe or cardioembolic stroke,
such as atrial fibrillation and heart failure [39,40], which may have partly accounted for
stroke severity or classification. Furthermore, we also lacked more information regarding
cancer staging except for the presence of metastases. We were thus unable to further
stratify our analyses by cancer stage. Our database also did not capture treatments such as
antithrombotic therapy, which may contribute to the differences in outcomes. Finally, our
study only assessed in-hospital outcomes and further research including is also required
to characterise the long-term stroke outcomes after hospital discharge associated with
co-morbid cancer as well as their interaction with revascularisation strategies.
5. Conclusions
In conclusion, in this study including a sample representative of 1.1 million AIS ad-
missions across the United States between 2015–2017, we reported that patients with cancer
represent one in thirty acute stroke admissions in the United States and are associated with
an increased risk of mortality. We also report that, even after adjustment for differences in
comorbidity, patients with cancer are less likely to be offered revascularisation therapies.
These disparities in care may contribute to some of the observed adverse outcomes associated
with a cancer diagnosis. Nevertheless, IVT offset the non-metastatic cancer-associated excess
odds of mortality, while ET offset both the non-metastatic and metastatic cancer-associated
excess odds of mortality. Both non-metastatic and metastatic cancers were associated with
increased odds of prolonged hospitalisation and decreased odds of routine discharge. IVT
and ET are useful strategies to improve in-hospital outcomes in this population and should
be offered routinely in cancer patients unless otherwise contraindicated.
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